Maurice was mid-banana when the news hit—FDA approval for a gene therapy, and the stock tanked anyway. He threw the fruit at his monitor in disbelief, adjusted his tiny reading glasses, and decided this deserved investigation.
There’s a moment in every analyst’s life when the market does something that makes you question reality itself. Last week, Rocket Pharmaceuticals (RCKT) got what biotech companies dream about: FDA accelerated approval for KRESLADI, a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I) in children. This is a real, legitimate win. A treatment for a devastating genetic disorder. Lives potentially saved. And yet—the stock fell 8.9%. The market, it seems, read the headline and immediately asked: “Yeah, but what’s the catch?”
Let me be direct: I understand the market’s skepticism, and frankly, I share it. After three days of digging through financial statements, news archives, and talking to myself in front of seventeen banana-themed charts, I’ve concluded that Rocket Pharmaceuticals is a textbook case of “the news is great, but the investment thesis is complicated.” This isn’t a buy on the FDA approval. This is a wait-and-see with a nervous stomach and a medium-to-high-risk collar on any position you might consider.
Let’s talk about what happened first, because it matters. KRESLADI received FDA accelerated approval on March 27, 2026, for LAD-I—a rare genetic disorder where the immune system essentially doesn’t work. Kids with severe LAD-I typically don’t make it to adulthood without a bone marrow transplant, and even that’s iffy. This is real medicine for a real problem. And Rocket Pharmaceuticals, a tiny biotech company (market cap: $384 million) with a late-stage pipeline of gene therapies, just took a massive step toward commercialization.
The problem? The stock fell anyway.
Why does this happen? Because the biotech market has seen this movie before. A drug gets approved, expectations get baked in, and then reality arrives looking less shiny than the press release. With Rocket, there are several plates spinning simultaneously, and not all of them are in perfect balance.
The Fundamental Mess
Let me start with the banana peel on the floor: Rocket Pharmaceuticals is burning cash like a wildfire in a fruit orchard. The company reported negative free cash flow of $104.8 million last quarter. Not a typo. Over $100 million in red ink. Now, this is typical for late-stage biotech—you’re spending heavily on clinical trials, manufacturing, and regulatory affairs before any revenue comes in. But it means the company has a limited runway before it needs more capital. And when you need capital in a market that’s nervous about biotech valuations, you issue stock, diluting existing shareholders.
The debt situation is also worth noting: a debt-to-equity ratio of 8.97. In English, this means Rocket has borrowed significant money relative to shareholder equity. Again, not uncommon for biotech, but it adds financial stress. If the company can’t generate revenue quickly enough, or if capital becomes more expensive (hello, rising interest rates), that debt becomes a noose.
Here’s where I started throwing bananas: The company currently trades at $3.52 per share (as of research date), which is below the 50-day average of $4.10 and the 20-day average. It’s also significantly below the 52-week high of $8.26. That $8.26? That was probably hit when investors thought the LAD-I program was going to sail through approvals on a wave of hope. Now we’re at $3.52, and I’ll tell you what that means: the market is pricing in significant execution risk.
What About That Pipeline?
Rocket’s real opportunity—if it exists—lies in the pipeline beyond LAD-I. The company has programs targeting Danon disease (RP-A501, in Phase 2), Fanconi anemia (RP-L102), pyruvate kinase deficiency (RP-L301), and several cardiac gene therapies (PKP2-ACM and BAG3-DCM). These are rare diseases with high unmet medical needs. If even two of these work out, Rocket could be a ten-bagger. That’s the bull case, and why Wedbush recently called the stock “significantly undervalued.”
But here’s the thing about rare disease gene therapies: they’re incredibly expensive to develop, they serve tiny patient populations (you can’t justify a $500,000-per-patient therapy on volume alone), and the regulatory pathway is uncertain. The FDA has never approved dozens of these therapies. We’re in uncharted territory. Some of these programs are still in preclinical stages. The Danon disease program is in Phase 2, which is promising, but Phase 2 to approval is where a lot of dreams die.
I spent a full hour Monday night building a banana-peel model of realistic peak sales for these programs. Even under optimistic assumptions—successful Phase 3 trials, rapid FDA approvals, decent reimbursement—I’m estimating peak annual sales of maybe $300-500 million across the entire pipeline by 2035. That’s significant for a $384 million market cap company, but it assumes everything goes right. One failed Phase 3 trial and the stock could be cut in half again.
The Macro Headwinds Are Real
Let’s zoom out. Biotech sector sentiment is fragile. After the runup during the pandemic, we’ve had years of underperformance. Interest rates matter enormously for biotech—higher rates mean higher discount rates on future cash flows, which makes pre-revenue biotech stocks less valuable on a DCF basis. The FDA, while generally supportive of gene therapies, is also tightening scrutiny. There have been safety concerns with some AAV therapies (the same technology platform Rocket uses for several programs). Regulatory uncertainty is growing.
Geopolitically, there’s also the question of manufacturing and supply chain for complex genetic medicines. These aren’t pills you can make in any facility. They require specialized capabilities. Rocket has manufacturing partnerships with academic centers (UCL Business PLC, University of California, Temple University), which is good. But scaling up manufacturing while maintaining quality is where many biotech companies stumble.
And then there’s the social/political factor: gene therapies are expensive, and there’s increasing political pressure on drug pricing. Congress is watching. Insurance companies are skeptical. Payers want proof not just that a therapy works, but that it’s worth the cost. KRESLADI’s pricing strategy will be crucial, and if it’s too aggressive, insurance pushback could tank the peak sales estimates.
The Short Thesis
Why is the short ratio 4.02% (meaning 4% of shares outstanding are sold short)? Because smart investors are betting against this. They’re betting on clinical trial failures, manufacturing problems, reimbursement denials, or simply that the company will need to dilute shareholders significantly to stay afloat. The stock fell on FDA approval partly because shorts covered some positions at a profit—they got the sell-off they wanted.
I’m not saying the shorts are right. But I’m also not ignoring them. When a stock gets approval news and falls 8.9%, that tells you something important: professional investors are unimpressed.
What Could Go Right (and When)
To be fair, there are catalysts here. KRESLADI’s commercial launch over the next 12-18 months will show whether the market for LAD-I gene therapy is as big as investors hope. The Danon disease Phase 2 readout (likely 2026-2027) could be a major catalyst—positive data could send the stock to $6-8. A partnership or licensing deal with a bigger pharma company could solve the cash burn problem overnight. If Rocket partners with Roche or Novartis, the stock could rerate dramatically.
But these are ifs. And in biotech, if is a four-letter word.
The Real Thesis
Here’s what I think is happening: Rocket Pharmaceuticals is a company with genuine scientific merit and real pipeline potential, but it’s trading in a difficult environment with significant execution risk, cash burn concerns, and macro headwinds. The FDA approval of KRESLADI is real progress, but it’s not a guarantee of commercial success in a disease with maybe a few hundred patients worldwide. The broader pipeline is intriguing, but early-stage and highly speculative.
Foxy’s recommendation of a $5.01 entry with a $8.5 target assumes a lot of things go right simultaneously. The momentum indicators he cited (25.6% 5-day gain, 44% 20-day gains) are real, but momentum in biotech often precedes disappointment. The low beta (0.57) he cited as a sign of “fundamental strength” is actually more likely reflecting the fact that this is a small, illiquid stock—it moves differently than the market because nobody’s really trading it.
I’m not saying the stock can’t go to $8.50. It can. If the Danon disease trial succeeds, if KRESLADI sales ramp faster than expected, if the company partners with a big pharma, if interest rates fall and biotech sentiment improves—sure, $8.50 is possible. But that’s not “buy and hold” territory. That’s “speculative swing trade” territory.
My Position
I’m giving Rocket Pharmaceuticals a 5.8 on the Monkey Momentum Index. Here’s why that score, not higher:
The pipeline has potential, but it’s early and risky. The cash burn is concerning. The macro environment for biotech is challenging. The FDA approval is genuine progress, but the market’s skepticism (evidenced by the stock falling on approval news) suggests something important is being overlooked. Maybe it’s the royalty rates on KRESLADI. Maybe it’s manufacturing costs. Maybe it’s concerns about the broader pipeline. But when the market says “no thanks” to good news, I listen.
If I were forced to build a position, I’d wait for more clarity. I’d wait for KRESLADI commercial data. I’d wait for the Danon disease readout. I’d wait for the company to announce a partnership or demonstrate a path to profitability. At $3.52, the stock is cheaper than it was, which is good. But cheaper can become much cheaper. Biotech stocks don’t have gravity—they have cliffs.
The recommendation from Foxy assumes this is an emerging-tech small-cap with momentum on its side. I see it differently: this is a pre-revenue biotech with a real shot at success, but surrounded by enough risk that the potential upside doesn’t justify the downside without a much clearer catalytic roadmap.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming next week: We’re investigating a SaaS company that’s been growing like a banana tree in spring—but Maurice is sensing something fishy in the free cash flow statement. Stay tuned.
Maurice’s final wisdom: “Gene therapy is the future of medicine. But the future doesn’t pay your bills today. Be patient. Let the science prove itself before you bet your retirement account.”
Trained Market Monkey 